Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

29.05.24	Merck To Acquire EyeBio; Deal Valued Up To $3 Bln (RTTNews)
29.05.24	Merck Nears $1.3 Bln Cash Deal To Buy EyeBio, With Potential $1.7 Bln In Milestone Payments : Report (RTTNews)
28.05.24	Merck Reports Positive Phase 3 KEYTRUDA Plus Chemotherapy Trial Results In TNBC Patients (RTTNews)
13.05.24	Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma (RTTNews)
09.05.24	Merck's Phase 3 Trial Of KEYTRUDA Plus Chemotherapy In Endometrial Cancer Fails To Meet Primary Goal (RTTNews)
09.05.24	Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults (RTTNews)
25.04.24	Merck Lifts FY24 Outlook After Higher Q1 Earnings, Above Market; Stock Up In Pre-market (RTTNews)
24.04.24	Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors (RTTNews)
19.04.24	Health Canada Approves Merck's Keytruda Plus Chemotherapy To Treat Gastric Cancers (RTTNews)
04.04.24	Merck Begins Phase 3 Trial Of MK-1084 As First-Line Treatment Of Certain Metastatic NSCLC Patients (RTTNews)
27.03.24	FDA Approves Merck's Winrevair For Treatment Of Pulmonary Arterial Hypertension In Adults (RTTNews)
12.03.24	IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer (RTTNews)
11.03.24	Merck Completes Acquisition Of Harpoon Therapeutics - Quick Facts (RTTNews)
28.02.24	Biotech Stocks Facing FDA Decision In March 2024 (RTTNews)
23.02.24	Merck Says Keytruda Combination Gets Positive EU CHMP Opinion As Neoadjuvant Treatment For NSCLC (RTTNews)
20.02.24	Merck: FDA Grants Priority Review To SBLA For KEYTRUDA Plus Chemotherapy In Endometrial Carcinoma (RTTNews)
12.02.24	Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy (RTTNews)
08.02.24	Merck Signs Multi-Year Agreement With Vector Institute (RTTNews)
05.02.24	Merck Animal Health To Buy Elanco's Aqua Business In $1.3 Bln Cash Deal; Elanco Up In Pre-market (RTTNews)
01.02.24	Merck Guides FY24 EPS Above Estimates As Q4 Results Top Estimates (RTTNews)
01.02.24	Merck Q4 Results Top Estimates; Guides FY24 Adj. EPS Above Estimates (RTTNews)
31.01.24	Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment (RTTNews)
29.01.24	Merck's Keytruda Reduces Risk Of Death By 38% In Adjuvant RCC Therapy In Phase 3 Trial (RTTNews)
25.01.24	LAVA Therapeutics In Deal With Merck For Clinical Trial Collaboration; Stock Surges In Pre-market (RTTNews)
13.01.24	Merck : FDA Approves KEYTRUDA Combination For Advanced Cervical Cancer Treatment (RTTNews)
08.01.24	Merck To Acquire Harpoon - Quick Facts (RTTNews)
08.01.24	Merck In Talks To Acquire Harpoon Therapeutics: Reports (RTTNews)
28.12.23	Biotech Stocks Facing FDA Decision In January 2024 (RTTNews)
22.12.23	Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan (RTTNews)
21.12.23	Merck: KEYTRUDA, LENVIMA Combination Receive Public Listing (RTTNews)
21.12.23	Merck: FDA Says Gefapixant NDA Did Not Meet Substantial Evidence Of Effectiveness To Treat RCC, UCC (RTTNews)
14.12.23	Moderna, Merck Announce Follow-up Data From Phase 2b KEYNOTE-942/mRNA-4157-P201 Study (RTTNews)
12.12.23	C4 Therapeutics, Merck Join To Develop Degrader-Antibody Conjugates (RTTNews)
11.12.23	Merck Animal Health Gets Positive CVMP Opinion For BRAVECTO Injectable Formulation For Use In Dogs (RTTNews)
08.12.23	Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints (RTTNews)
07.12.23	Merck Stops KEYTRUDA Trial After Failing To Meet Secondary Endpoint In Metastatic Lung Cancer (RTTNews)
07.12.23	Merck Reports Data From Phase 2 KeyVibe-002 Trial - Quick Facts (RTTNews)
30.11.23	Biotech Stocks Facing FDA Decision In December 2023 (RTTNews)
21.11.23	Merck To Acquire Caraway Therapeutics (RTTNews)
14.11.23	Natera Signs Real-World Data Collaboration With Merck (RTTNews)
14.11.23	Agilent Technologies Announces FDA Approval For PD-L1 IHC 22C3 PharmDx - Quick Facts (RTTNews)
28.10.23	Biotech Stocks Facing FDA Decision In November 2023 (RTTNews)
26.10.23	Merck Reports Higher Profit For Q3; Revises Full-year Outlook (RTTNews)
25.10.23	Merck: KEYTRUDA Plus LENVIMA Is Available In Canada To Treat Advanced Or Metastatic Kidney Cancer (RTTNews)
23.10.23	Immutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLC (RTTNews)
20.10.23	Merck Reveals Positive Results From Phase 3 KEYTRUDA Trials In Various Cancers (RTTNews)
20.10.23	Daiichi Sankyo, Merck Reach $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates (RTTNews)
20.10.23	Daiichi Sankyo, Merck Reach Up To $22 Bln Worth Agreement On Antibody Drug Conjugate Candidates (RTTNews)
16.10.23	EC Approves Merck's KEYTRUDA As Adjuvant Treatment For Non-Small Cell Lung Cancer (RTTNews)
10.10.23	Merck: KEYNOTE-671 Trial Meets Dual Primary Endpoint - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’332.00	5.67 %	K V
Logitech Intl	79.94	2.78 %	K V
Lonza Grp	551.80	1.85 %	K V
Sonova Hldg	298.10	1.29 %	K V
UBS Group	29.54	1.13 %	K V
Zurich Insur Gr	546.60	-0.26 %	K V
Holcim	88.14	-0.38 %	K V
ABB	49.39	-0.44 %	K V
Kuehne+Nagel Int	208.40	-0.48 %	K V
Sika	216.10	-0.73 %	K V

mehr

11:09		Bayer-Aktie höher: Bayer beantragt China-Zulassung für Prostatakrebsmedikament
10:29		Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) bescheinigt Hold für Novartis-Aktie
10:02		EURO STOXX 50-Titel Sanofi-Aktie: So viel Gewinn hätte eine Investition in Sanofi von vor einem Jahr abgeworfen
09:28		Starker Wochentag in Frankfurt: LUS-DAX zum Start in der Gewinnzone
09:28		Zurückhaltung in London: FTSE 100 zum Start des Dienstagshandels im Minus
09:28		Dienstagshandel in Zürich: SPI verliert zum Start des Dienstagshandels
09:28		Dienstagshandel in Zürich: SLI beginnt die Sitzung im Minus
09:28		Börse Europa in Rot: STOXX 50 zum Handelsstart in der Verlustzone

11:09

Bayer-Aktie höher: Bayer beantragt China-Zulassung für Prostatakrebsmedikament

10:29

Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) bescheinigt Hold für Novartis-Aktie

10:02

EURO STOXX 50-Titel Sanofi-Aktie: So viel Gewinn hätte eine Investition in Sanofi von vor einem Jahr abgeworfen

09:28

Starker Wochentag in Frankfurt: LUS-DAX zum Start in der Gewinnzone

09:28

Zurückhaltung in London: FTSE 100 zum Start des Dienstagshandels im Minus

09:28

Dienstagshandel in Zürich: SPI verliert zum Start des Dienstagshandels